Cytokinetics | CYTK - Net Income


Cytokinetics reported $-206.03M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 31.5M 27.86M Jun/2026
Amgen USD 2.38B 556M Jun/2026
Arca Biopharma USD -31.82M 2.24M Mar/2026
Bayer EUR 2.76B 6.52B Mar/2026
Biogen USD 97.5M 222M Jun/2026
Brainstorm Cell Therapeutics USD -2.13M 21K Mar/2026
Bristol-Myers Squibb USD 3.32B 640M Jun/2026
Capricor Therapeutics USD -30.17M 5.6M Dec/2025
Cytokinetics USD -206.03M 23M Mar/2026
Eisai JPY 18.24B 21.49B Jun/2026
Eli Lilly USD 7.1B 301M Jun/2026
Exelixis USD 210.47M 34.06M Mar/2026
Geron USD -3.64M 27.5M Mar/2026
Halozyme Therapeutics USD 150.05M 291.64M Mar/2026
Ionis Pharmaceuticals USD -114.65M 21.65M Jun/2026
Ligand Pharmaceuticals USD 48.51M 61.85M Jun/2026
Merck USD -1.34B 2.9B Jun/2026
Novartis USD 3.26B 108M Jun/2026
Pfizer USD -248M 2.94B Jun/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sanofi EUR 343M 1.27B Jun/2026